Kala Bio Inc (KALA)

$7.63

+0.76

(+11.06%)

Market is closed - opens 8 PM, 11 Nov 2024

Performance

  • $6.85
    $7.83
    $7.63
    downward going graph

    10.22%

    Downside

    Day's Volatility :12.52%

    Upside

    2.55%

    downward going graph
  • $4.21
    $10.97
    $7.63
    downward going graph

    44.82%

    Downside

    52 Weeks Volatility :61.62%

    Upside

    30.45%

    downward going graph

Returns

PeriodKala Bio Inc
3 Months
30.43%
6 Months
13.66%
1 Year
29.98%
3 Years
-92.9%

Highlights

Market Capitalization
37.7M
Book Value
$2.98
Earnings Per Share (EPS)
-13.52
PEG Ratio
0.0
Wall Street Target Price
15.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-40.25%
Return On Equity TTM
-248.11%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
1.3M
EBITDA
-41.0M
Diluted Eps TTM
-13.52
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-11.75
EPS Estimate Next Year
-6.67
EPS Estimate Current Quarter
-4.4
EPS Estimate Next Quarter
-4.53

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Kala Bio Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 96.59%

Current $7.63
Target $15.00

Technicals Summary

Sell

Neutral

Buy

Kala Bio Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Kala Bio Inc
Kala Bio Inc
46.03%
13.66%
29.98%
-92.9%
-96.14%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-18.16%
-14.42%
3.52%
34.42%
140.62%
Biontech Se
Biontech Se
-5.81%
20.18%
11.4%
-51.12%
460.49%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
2.41%
83.28%
68.63%
50.84%
200.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
10.42%
23.33%
40.2%
170.42%
155.94%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Kala Bio Inc
Kala Bio Inc
11.21
NA
0.0
-11.75
-2.48
-0.4
NA
2.98
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
20.41
20.41
1.2
44.89
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.1
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-1.87
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.27
0.19
-0.03
0.13
NA
60.66
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Kala Bio Inc
Kala Bio Inc
Buy
$37.7M
-96.14%
11.21
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$90.6B
140.62%
20.41
33.61%
Biontech Se
Biontech Se
Buy
$25.9B
460.49%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$35.1B
200.09%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.9B
155.94%
32.84
-4.51%

Institutional Holdings

  • Baker Bros Advisors LP

    19.35%
  • SR ONE CAPITAL MANAGEMENT, LP

    9.63%
  • ADAR1 Capital Management LLC

    6.64%
  • UBS O'Connor LLC

    3.20%
  • Millennium Management LLC

    3.09%
  • Vanguard Group Inc

    1.09%

Company Information

kala pharmaceuticals, inc. (kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based mucus penetrating particles, or mpp, technology, with an initial focus on the treatment of eye diseases. for more information, please visit kala’s website at www.kalarx.com.

Organization
Kala Bio Inc
Employees
43
CEO
Mr. Mark T. Iwicki
Industry
Health Technology

FAQs